Fig. 5: FTO deficiency enhances Fas mRNA stability in CD8+ T cells.
From: FTO controls CD8+ T cell survival and effector response by modulating m6A methylation of Fas
A The mRNA expression of Fas in WT (Ftofl/flCD4-Cre−) and FTO KO (Ftofl/flCD4-Cre+) CD8+ T cells stimulated in vitro with anti-CD3/CD28 antibodies at indicated timepoints was measured by qPCR (n = 3). B mRNA decay assay showing the remaining content of Fas mRNA measured by qPCR in WT and FTO KO CD8+ T cells with ActD treatment. The remaining mRNAs were normalized to 0 h (n = 3). C The mRNA levels of Fas in (B) at different timepoints after ActD treatment (n = 3). D–F WT and FTO KO CD8+ T cells were stimulated with anti-CD3/CD28 antibodies for 12 h before adding in CHX treatment at different timepoints (n = 3). The representative flow cytometry plots (D) and MFI (E) of Fas expression on WT and FTO KO CD8+ T cells. CHX administration was marked with the arrow at 0 h, and naïve cells were indicated as −12 h. F The Fas expression on WT and FTO KO CD8+ T cells after CHX treatment was normalized to 0 h. G–I WT and FTO KO CD8+ T cells were stimulated with anti-CD3/CD28 antibodies for 4 h before adding in MG132 treatment at different timepoints (n = 3). The representative flow cytometry plots (G) and MFI (H) of Fas expression on WT and FTO KO CD8+ T cells. MG132 administration was marked with the arrow at 0 h, and naïve cells were indicated as −4 h. I The Fas expression on WT and FTO KO CD8+ T cells after MG132 treatment was normalized to 0 h. Data are representative of two or three independent experiments shown as the mean ± SD. Statistical testing is depicted as two-sided, unpaired t-tests; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
